CytomX Therapeutics (CTMX) Stock Forecast & Price Target

CytomX Therapeutics is viewed positively because Varseta-M has already shown credible late-line CRC activity, with 20%-32% confirmed ORR and 6.8-7.1 months mPFS in heavily pretreated patients, materially ahead of typical low-single-digit ORRs and short PFS for current options. The 2H26 data update should provide longer OS follow-up plus the 40-patient dose-optimization readout, which could confirm whether enhanced prophylaxis and AIBW dosing keep Grade 3 diarrhea near the 10%-20% target and support a 3L development path. Its outlook is further strengthened by expansion into non-CRC EpCAM tumors, progressing combination studies, and a strong balance sheet of $330M in cash at 2Q26 plus $37M received in July, supporting a runway into at least 2H28.

CytomX Therapeutics is viewed negatively because its value is still anchored to a high-risk clinical pipeline, with significant R&D, regulatory, and commercial execution risk centered on CX-2051 in 3L colorectal cancer and on Varseta-M tolerability and positioning. Although the company ended 1Q26 with $346.7M in cash, equivalents, and investments, including $234.2M of March 2026 offering proceeds, the financing also raised dilution concerns and only funds operations through at least 2H28, leaving the stock dependent on multiple trial readouts in 2H26 and 1H27. The outlook is further weakened by the possibility of trial delays, unfavorable data, lower-than-expected product sales, and new competitors, which collectively cap confidence in durable commercial traction.